Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA

Delayed Quote. Delayed  - 05/31 10:00:00 pm
1.81 USD   +3.43%
05/09 ARENA PHARMACEU : reports 1Q loss
05/09 ARENA PHARMACEU : Announces Appointment of Amit D. Munshi as Preside..
05/09 ARENA PHARMACEU : Reports First Quarter 2016 Financial Results and P..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Arena Pharmaceuticals, Inc. : Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2013 | 03:05pm CEST

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares hit a low of $7.70 Friday before settling to close at $7.78, a decrease of 6.71 percent. The stock traded in between $7.70 to $8.30 on volume of 8.97 million shares traded. Consumer Reports has recently advised their readers to ?skip? Arena?s weight loss drug, Belviq.

Get more information on Arena Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARNA

E I Du Pont De Nemours And Co (NYSE: DD) shares hit a low of $52.16 Friday before settling to close at $52.68, a decrease of 2.23 percent. The stock traded in between $52.16 to $53.70 on volume of 11.28 million shares traded. Jefferies Group currently has a ?hold? rating on the stock and has recently raised its price target on the company to $56.00 from $52.00.

Get more information on Du Pont and free access to the in-depth equity report at:
www.FiveStarEquities.com/DD

The Kroger Co. (NYSE: KR) hit a low of $34.67 Friday before settling to close at $34.79, a decrease of 0.77 percent. The stock traded in between $34.67 to $35.25 on volume of 2.46 million shares traded. Argus currently has a ?buy? rating on the stock and has recently raised its price target on the company to $40.00 from $34.00.

Get more information on Kroger and free access to the in-depth equity report at:
www.FiveStarEquities.com/KR

Veeco Instruments Inc. (NASDAQ: VECO) shares hit a low of $37.74 Friday before settling to close at $38.10, a decrease of 3.20 percent. The stock traded in between $37.74 and $39.04 on volume of 559,990 shares traded. UBS has reiterated it ?neutral? view on the company due to pricing pressure pricing pressure Veeco?s metal organic vapor deposition epitaxial systems.

Get more information on Veeco Instruments and free access to the in-depth equity report at:
www.FiveStarEquities.com/VECO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ARENA PHARMACEUTICALS, INC
05/19 ARENA PHARMACEUTICALS : Reports First Quarter 2016 Financial Results and Provide..
05/09 ARENA PHARMACEUTICALS : reports 1Q loss
05/09 ARENA PHARMACEUTICALS : Announces Appointment of Amit D. Munshi as President and..
05/09 ARENA PHARMACEUTICALS : Reports First Quarter 2016 Financial Results and Provide..
05/02 ARENA PHARMACEUTICALS : to Host First Quarter 2016 Financial Results and Corpora..
04/21 ARENA PHARMACEUTICALS : Reports Favorable Results from Phase 1b Multiple-Ascendi..
04/16 ARENA PHARMACEUTICALS : Perrigo Firm, Arena Pharmaceuticals, Actinium Pharmaceut..
04/13 ARENA PHARMACEUTICALS' : APD371 pain drug succeeds in early-stage test
04/12 ARENA PHARMACEUTICALS : Reports Favorable Results from Phase 1b Multiple-Ascendi..
03/10 ARENA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2015 Financial Resu..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials